JP7062003B2 - ポックスウイルス内における導入遺伝子の安定性を向上させるための組成物及び方法 - Google Patents

ポックスウイルス内における導入遺伝子の安定性を向上させるための組成物及び方法 Download PDF

Info

Publication number
JP7062003B2
JP7062003B2 JP2019516437A JP2019516437A JP7062003B2 JP 7062003 B2 JP7062003 B2 JP 7062003B2 JP 2019516437 A JP2019516437 A JP 2019516437A JP 2019516437 A JP2019516437 A JP 2019516437A JP 7062003 B2 JP7062003 B2 JP 7062003B2
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
recombinant poxvirus
recombinant
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019516437A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528755A5 (enExample
JP2019528755A (ja
Inventor
カッラ・マルクス
ラウントリー・ライアン
ディルマイアー・ウルリーケ
Original Assignee
バヴァリアン・ノルディック・アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バヴァリアン・ノルディック・アクティーゼルスカブ filed Critical バヴァリアン・ノルディック・アクティーゼルスカブ
Publication of JP2019528755A publication Critical patent/JP2019528755A/ja
Publication of JP2019528755A5 publication Critical patent/JP2019528755A5/ja
Application granted granted Critical
Publication of JP7062003B2 publication Critical patent/JP7062003B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
JP2019516437A 2016-09-28 2017-09-28 ポックスウイルス内における導入遺伝子の安定性を向上させるための組成物及び方法 Active JP7062003B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662401035P 2016-09-28 2016-09-28
US62/401,035 2016-09-28
PCT/EP2017/074693 WO2018060368A2 (en) 2016-09-28 2017-09-28 Compositions and methods for enhancing the stability of transgenes in poxviruses

Publications (3)

Publication Number Publication Date
JP2019528755A JP2019528755A (ja) 2019-10-17
JP2019528755A5 JP2019528755A5 (enExample) 2020-09-24
JP7062003B2 true JP7062003B2 (ja) 2022-05-02

Family

ID=60083287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019516437A Active JP7062003B2 (ja) 2016-09-28 2017-09-28 ポックスウイルス内における導入遺伝子の安定性を向上させるための組成物及び方法

Country Status (11)

Country Link
US (2) US11052139B2 (enExample)
EP (1) EP3518964A2 (enExample)
JP (1) JP7062003B2 (enExample)
KR (1) KR102605505B1 (enExample)
CN (1) CN110198733B (enExample)
AU (1) AU2017336269B2 (enExample)
CA (1) CA3036799C (enExample)
IL (1) IL265539B (enExample)
RU (1) RU2756534C2 (enExample)
WO (1) WO2018060368A2 (enExample)
ZA (1) ZA201901756B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210046130A1 (en) * 2018-01-24 2021-02-18 Virogin Biotech Canada Ltd Recombinant viral vaccines
EP3847246A1 (en) * 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP3988650A4 (en) * 2019-06-21 2022-09-21 Osaka University METHOD OF PRODUCING AN ARTIFICIAL RECOMBINANT RNA VIRUS THAT KEEPS A FOREIGN GENE STABLE
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526520A (ja) 2002-05-24 2005-09-08 グラクソ　グループ　リミテッド Ｖｎｔｒ反復ユニットの数が減少したｍｕｃ−１抗原
JP2007510755A (ja) 2003-11-12 2007-04-26 セリオン・バイオロジックス・コーポレーション 乳癌を処置および予防するためのシステム

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122599A (en) 1986-08-13 1992-06-16 Molecular Diagnostics, Inc. CDNAS coding for members of the carcinoembryonic antigen family
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
EP0954593A1 (en) 1996-07-25 1999-11-10 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
EP1456230A2 (en) 2001-12-04 2004-09-15 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
GB0304634D0 (en) 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
JP5060134B2 (ja) * 2003-12-12 2012-10-31 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ
EP1985305A1 (en) * 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
CA2741724C (en) 2008-11-27 2016-10-04 Bavarian Nordic A/S Promoters for recombinant viral expression
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
WO2013103658A1 (en) * 2012-01-03 2013-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Native and agonist ctl epitopes of the muc1 tumor antigen
US10111946B2 (en) 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
MX380483B (es) 2012-10-28 2025-03-12 Bavarian Nordic As Promotor pr13.5 para respuestas de anticuerpos y linfocitos t fuertes.
AU2014340201B2 (en) 2013-10-23 2019-02-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526520A (ja) 2002-05-24 2005-09-08 グラクソ　グループ　リミテッド Ｖｎｔｒ反復ユニットの数が減少したｍｕｃ−１抗原
JP2007510755A (ja) 2003-11-12 2007-04-26 セリオン・バイオロジックス・コーポレーション 乳癌を処置および予防するためのシステム

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"ACCESSION: AAI72490 (DEFINITION: H6-promoter human CEAmod/42K-promoted B7.1 insertion casette)", NCBI Seqence Revision History [online], 2002.5.16, uploaded, NCBI, [retrived on 2021.4.15], retrived from the Internet
"ACCESSION: AAI72490 (DEFINITION: H6-promoter human CEAmod/42K-promoted B7.1 insertion casette)", NCBI Sequence Revision History [online], 2002.5.16, uploaded, NCBI, [retrieved on 2021.4.15], retrieved from the Internet
"ACCESSION: AAQ03654 (DEFINITION: Insert from phase lambda HT16 encoding integrated membrane form of LFA-3)", NCBI Seqence Revision History [online], 2007.6.11, uploaded, NCBI, [retrived on 2021.4.15], retrived from the Internet
"ACCESSION: AAQ03654 (DEFINITION: Insert from phase lambda HT16 encoding integrated membrane form of LFA-3)", NCBI Sequence Revision History [online], 2007.6.11, uploaded, NCBI, [retrieved on 2021.4.15], retrieved from the Internet
"ACCESSION: AAQ21171 (DEFINITION: Clone encodiing Intercellular Adhesion Molecule-1)", NCBI Seqence Revision History [online], 2003.5.25, uploaded, NCBI, [retrived on 2021.4.15], retrived from the Internet
"ACCESSION: AAQ21171 (DEFINITION: Clone encodiing Intercellular Adhesion Molecule-1)", NCBI Sequence Revision History [online], 2003.5.25, uploaded, NCBI, [retrieved on 2021.4.15], retrieved from the Internet
"ACCESSION: ADZ58978 (DEFINITION: Novel CEA(6)-1,2 expression vector-related mCEA DNA sequence SeqID8)", NCBI Seqence Revision History [online], 2005.4.21, uploaded, NCBI, [retrived on 2021.4.15], retrived from the Internet
"ACCESSION: ADZ58978 (DEFINITION: Novel CEA(6)-1,2 expression vector-related mCEA DNA sequence SeqID8)", NCBI Sequence Revision History [online], 2005.4.21, uploaded, NCBI, [retrieved on 2021.4.15], retrieved from the Internet
"ACCESSION: FB574355 (DEFINITION: Sequence 28 from Patent EP1864691)", NCBI Seqence Revision History [online], 2007.12.12, uploaded, NCBI, [retrived on 2021.4.15], retrived from the Internet
"ACCESSION: FB574355 (DEFINITION: Sequence 28 from Patent EP1864691)", NCBI Sequence Revision History [online], 2007.12.12, uploaded, NCBI, [retrieved on 2021.4.15], retrieved from the Internet

Also Published As

Publication number Publication date
US11654189B2 (en) 2023-05-23
US20200061174A1 (en) 2020-02-27
RU2756534C2 (ru) 2021-10-01
JP2019528755A (ja) 2019-10-17
IL265539B (en) 2022-03-01
KR102605505B1 (ko) 2023-11-22
AU2017336269B2 (en) 2022-06-16
US20210338788A1 (en) 2021-11-04
US11052139B2 (en) 2021-07-06
CA3036799A1 (en) 2018-04-05
EP3518964A2 (en) 2019-08-07
CN110198733A (zh) 2019-09-03
CA3036799C (en) 2025-05-13
AU2017336269A1 (en) 2019-04-11
NZ752275A (en) 2025-07-25
WO2018060368A3 (en) 2019-02-07
IL265539A (en) 2019-05-30
KR20190053272A (ko) 2019-05-17
CN110198733B (zh) 2024-04-30
WO2018060368A2 (en) 2018-04-05
RU2019112725A (ru) 2020-10-29
ZA201901756B (en) 2022-07-27
RU2019112725A3 (enExample) 2020-12-09

Similar Documents

Publication Publication Date Title
US11654189B2 (en) Compositions and methods for enhancing the stability of transgenes in poxviruses
JP6818797B2 (ja) 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答
EP2864487B1 (en) Poxviral vectors for low antibody response after a first priming immunization
JP6851364B2 (ja) ポックスウイルスにおける発現を増強するためのプロモーター
JP2011067219A (ja) 改変ワクシニアウイルスアンカラにおける発現用プロモーター
JP2020531524A5 (enExample)
US7300658B2 (en) Recombinant poxvirus comprising at least two compox ATI promoters
JP2018523491A (ja) 組換えオルフウイルスベクター
HK40013360B (en) Compositions and methods for enhancing the stability of transgenes in poxviruses
JP7034818B2 (ja) 増殖性ヘルパーワクシニアウイルスを使用するポックスウイルスの製造方法
HK40013360A (en) Compositions and methods for enhancing the stability of transgenes in poxviruses
BR112018002172B1 (pt) Promotores para intensificar a expressão em poxvírus
HK1254405B (en) Promoters for enhancing expression in poxviruses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200813

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220131

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220406

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220419

R150 Certificate of patent or registration of utility model

Ref document number: 7062003

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250